Copyright
©The Author(s) 2023.
World J Gastroenterol. Oct 7, 2023; 29(37): 5327-5338
Published online Oct 7, 2023. doi: 10.3748/wjg.v29.i37.5327
Published online Oct 7, 2023. doi: 10.3748/wjg.v29.i37.5327
Figure 2 Effect of semaglutide on histologic parameters.
A: Resolution of non-alcoholic steatohepatitis (NASH) with no worsening of liver fibrosis; B: Improvement in liver fibrosis stage without worsening of NASH; C: Improvement in steatosis; D: Improvement in lobular inflammation; E: Improvement in hepatocellular ballooning. 95%CI: 95% confidence intervals.
- Citation: Zhu K, Kakkar R, Chahal D, Yoshida EM, Hussaini T. Efficacy and safety of semaglutide in non-alcoholic fatty liver disease. World J Gastroenterol 2023; 29(37): 5327-5338
- URL: https://www.wjgnet.com/1007-9327/full/v29/i37/5327.htm
- DOI: https://dx.doi.org/10.3748/wjg.v29.i37.5327